NexLife Tirzepatide Review: Cost, a Required Video Visit & Honest Verdict (2026)

NexLife's site rate-limited this review's verification attempt, so its LegitScript claim couldn't be independently reconfirmed this check. It stands out for requiring a live video visit before any prescription — a stricter clinical standard than most compounded telehealths here. Every fact here comes from the company's own published program.

A rate-limited verification attempt

This review attempted to independently verify NexLife's LegitScript claim directly, but the site returned a rate-limit response rather than page content on repeated attempts — the claim is presented here rather than this check.

What NexLife is

NexLife is a telehealth platform, offering compounded semaglutide and tirzepatide, working exclusively with LegitScript-certified, NABP-accredited pharmacies — per the ranking's own research, among the strongest pharmacy trust signals documented on this site. A live video visit is required before any prescription is issued.

What NexLife costs

Semaglutide starts from $145/month on a 12-month plan ($165/month month-to-month) and tirzepatide from $186/month — among the lowest rates documented, though the lowest advertised prices require a full 12-month commitment.

The brand-vs-compounded question

NexLife dispenses compounded semaglutide and tirzepatide only — no brand-name option. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

NexLife's real strengths is a required live video visit before prescribing — a stricter clinical standard than many compounded competitors — plus exclusively LegitScript-certified, NABP-accredited pharmacy partners and competitive pricing at both molecules. The trade-offs: state availability isn't publicly disclosed, it's compounded only, the platform also covers hormone optimization and longevity rather than a single GLP-1 focus, and the lowest advertised rates require a 12-month commitment. This review's own live verification attempt was also blocked by a persistent rate limit, so treat the LegitScript claim as rather than freshly confirmed. As with any GLP-1 program, confirm your state's eligibility directly; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

NexLife's required live video visit and NABP-accredited pharmacy partners are real positives but this review couldn't independently reconfirm any of it live due to a persistent rate limit. For a provider with a fully confirmed clinical structure this review has verified live, compare it against NewSelf or CoreAge Rx. See our best tirzepatide providers ranking for the full field.